Figure 2: Impact of CD184 expression on overall survival (OS) in acute myeloid leukemia (AML) patients. This graph displays Kaplan– Meier estimates of OS of AML patients on the basis of CD184 expression on the leukemia cells at the time of diagnosis. OS was calculated for patients with low CD184 expression as defined by mean fluorescence intensity ratios (MFIRs) between 4 and 8 (group, n = 10), intermediate CD184 expression with MFIRs between 9 and 20 (group II, n = 6), and high CD184 expression with MFIRs equal to or more than 21 (group III, n = 4). Higher CXCR4 MFIRs correlated with a reduced OS. Log rank = 42.47; P = 0.0000.